Go Search
Home
Contact Us | Effient (prasugrel) tablets
Site Map | Effient (prasugrel) tablets
About the Partnership | Effient (prasugrel) tablets
Pharmacodynamics | Effient (prasugrel) tablets
Pharmacokinetics | Effient (prasugrel) tablets
Genetic Variations | Effient (prasugrel) tablets
Effient® (prasugrel) tablets | Clinical Study
High-risk NSTEMI Patient Case | Effient (prasugrel) tablets
STEMI Patient Case | Effient (prasugrel) tablets
NSTEMI Patient With Diabetes | Effient (prasugrel) tablets
Stent Thrombosis in All ACS | Effient (prasugrel) tablets
Safety in TRITON-TIMI 38 | Effient (prasugrel) tablets
Effient® (prasugrel) tablets | Indication and ISI
Effient® (prasugrel) tablets | Prescribing Information
Effient® (prasugrel) tablets | Recommended Dosing
Effient® (prasugrel) tablets | Concomitant Medication
Effient® (prasugrel) tablets | Storage and Handling
Patient Resources | Effient (prasugrel) tablets
Bleeding Rates by Patient Subgroups | Effient (prasugrel) tablets
Bleeding Rates by Weight and Age | Effient (prasugrel) tablets
Bleeding Rates in All ACS | Effient (prasugrel) tablets
Effient® (prasugrel) tablets | ACCF/AHA/SCAI Guideline for PCI
Effient® (prasugrel) tablets | ACCF/AHA STEMI Guideline
Primary composite endpoint: STEMI through 15 months
Primary composite endpoint: STEMI subgroups through 15 months
Secondary endpoint: stent thrombosis in all ACS and STEMI
Secondary endpoint: STEMI through day 30
Stent Thrombosis by Stent Type | Effient (prasugrel) tablets
Primary composite endpoint: UA/NSTEMI through 15 months
Secondary endpoint: stent thrombosis in all ACS and UA/NSTEMI
Secondary endpoint: UA/NSTEMI through day 30
Effient® (prasugrel) tablets | ACCF/AHA UA/NSTEMI Guideline Update
Primary composite endpoint: UA/NSTEMI through 15 months
Primary composite endpoint: UA/NSTEMI subgroups through 15 months
Secondary endpoint: stent thrombosis in all ACS and UA/NSTEMI
Secondary endpoint: UA/NSTEMI through day 30
Effient® (prasugrel) | STEMI-PCI Patients - Reductions Through Day 7
Effient® (prasugrel) | STEMI-PCI Patients - North American Subgroup
Effient® (prasugrel) | UA/NSTEMI-PCI Patients - Reductions Through Day 7
Effient® (prasugrel) | UA/NSTEMI-PCI Patients - North American Subgroup
The first round was tough enough. I'd rather not go a second round

STEMI-PCI PATIENTS

See why Effient may be appropriate for your STEMI-PCI patients at high risk of going a second round.

Review the data

UA/NSTEMI-PCI PATIENTS

See why Effient may be appropriate for your UA/NSTEMI-PCI patients at high risk of going a second round.

Review the data

ACS-PCI PATIENTS
WITH DIABETES

See why Effient may be appropriate for your ACS-PCI patients with diabetes at high risk of going a second round.

Review the data

FREE 30-DAY VOUCHER AND CO-PAY ASSISTANCE

Effient offers a free 30-day prescription voucher to help your patients start therapy and co-pay assistance to reduce out-of-pocket costs for your patients taking Effient.

Learn More

Effient® physician site homepage image Effient® physician site homepage image Effient® physician site homepage image

INDICATION

Effient® (prasugrel) is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows:

  • Patients with unstable angina (UA) or non–ST-elevation myocardial infarction (NSTEMI)
  • Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI

The loading dose (LD) of Effient is 60 mg and the maintenance dose (MD) is 10 mg once daily. Effient is available in 5-mg and 10-mg tablets.

IMPORTANT SAFETY INFORMATION

WARNING: BLEEDING RISK

Effient® (prasugrel) can cause significant, sometimes fatal, bleeding.

Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke.

In patients ≥75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered.

Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.

Additional risk factors for bleeding include:

  • body weight <60 kg
  • propensity to bleed
  • concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs])

Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient.

If possible, manage bleeding without discontinuing Effient. Discontinuing Effient, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events.

CONTRAINDICATIONS

  • Effient is contraindicated in patients with active pathological bleeding, such as from a peptic ulcer or intracranial hemorrhage (ICH), or a history of transient ischemic attack (TIA) or stroke, and in patients with hypersensitivity to prasugrel or any component of the product

WARNINGS AND PRECAUTIONS

  • Patients who experience a stroke or TIA while on Effient generally should have therapy discontinued. Effient should also be discontinued for active bleeding and elective surgery
  • Premature discontinuation of Effient increases risk of stent thrombosis, MI, and death
  • Thrombotic thrombocytopenic purpura (TTP), a rare but serious condition that can be fatal, has been reported with Effient, sometimes after a brief exposure (<2 weeks), and requires urgent treatment, including plasmapheresis
  • Hypersensitivity, including angioedema, has been reported in patients receiving Effient, including patients with a history of hypersensitivity reaction to other thienopyridines

ADVERSE REACTIONS

  • Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction

Please see Prescribing Information, including Boxed Warning regarding bleeding risk, and Medication Guide.